Ligand- and heterodimer-directed signaling of the CB1 cannabinoid receptor

Molecular Pharmacology

Volumn 77, Issue 1, 2010, Pages 1-9

  Hudson, Brian D ^a   Hébert, Terence E ^c   Kelly, Melanie E M ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; ICOSANOID; O 2050; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ALLOSTERISM; DIMERIZATION; DRUG CONFORMATION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; LIGAND BINDING; MOLECULAR MECHANICS; NONHUMAN; PARTIAL AGONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SHORT SURVEY; SIGNAL TRANSDUCTION;

HUMANS; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 73549098434     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060251     Document Type: Short Survey

References (83)

1. 1 receptor in constitutive activation of Gs. J Neurochem 72:2032-2038.
2. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10:870-879.
3. 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A 97:3684-3689.
4. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Piñeyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100:11406-11411.
5. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
6. 1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets 12:1347-1366.
7. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
8. Bilsland LG and Greensmith L (2008) The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 14:2306-2316.
9. Blake AD, Bot G, Freeman JC, and Reisine T (1997) Differential opioid agonist regulation of the mouse μ opioid receptor. J Biol Chem 272:782-790.
10. Bond RA and Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27:92-96.
11. Bonhaus DW, Chang LK, Kwan J, and Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884-888.
12. Bosier B and Hermans E (2007) Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci 28:438-446.
13. 1 receptor. Br J Pharmacol 155:24-33.
14. 1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. FEBS Lett 582:3861-3867.
15. Bosier B, Tilleux S, Najimi M, Lambert DM, and Hermans E (2007) Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J Neurochem 102:1996-2007.
16. Breit A, Gagnidze K, Devi LA, LagacéM, and Bouvier M (2006) Simultaneous activation of the δ opioid receptor (δOR)/sensory neuron-specific receptor-4 (SNSR-4) hetero-oligomer by the mixed bivalent agonist bovine adrenal medulla peptide 22 activates SNSR-4 but inhibits δOR signaling. Mol Pharmacol 70:686-696.
17. 3-adrenergic receptors generates a β-adrenergic signaling unit with distinct functional properties. J Biol Chem 279:28756-28765.
18. 1 receptor. Eur J Pharmacol 374:445-455.
19. Carriba P, Navarro G, Ciruela F, FerréS, CasadóV, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, et al. (2008) Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 5:727-733.
20. 1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32:2249-2259.
21. Charles AC, Mostovskaya N, Asas K, Evans CJ, Dankovich ML, and Hales TG (2003) Coexpression of δ-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol Pharmacol 63:89-95.
22. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
23. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 86:7321-7325.
24. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179-202.
25. Dalrymple MB, Pfleger KD, and Eidne KA (2008) G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol Ther 118:359-371.
26. Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, and Portoghese PS (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102:19208-19213.
27. Demuth DG and Molleman A (2006) Cannabinoid signalling. Life Sci 78:549-563.
28. 2-adrenergic receptor. J Biol Chem 283:5669-5676.
29. 1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824.
30. 1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-297.
31. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
32. Gardner A and Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 530:103-106.
33. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ- and β-opioid receptors. Generation of novel functional properties. J Biol Chem 275:26128-26135.
34. 1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 581:19-29.
35. Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113.
36. 1 receptor. J Neurosci 17:5327-5333.
37. 2 receptors. Mol Pharmacol 56:1362-1369.
38. 2 dopamine receptors. Br J Pharmacol 121:731-736.
39. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384-16392.
40. 1 receptors with hypophagic effects in rats. Br J Pharmacol 152:805-814.
41. Hosking RD and Zajicek JP (2008) Therapeutic potential of cannabis in pain medicine. Br J Anaesth 101:59-68.
42. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
43. 2 receptor signaling. 18th Annual Symposium of the International Cannabinoid Research Society; 2008 June 26-29; Aviemore, Scotland, pp 4, International Cannabinoid Research Society, Burlington, VT.
44. Jacoby E, Bouhelal R, Gerspacher M, and Seuwen K (2006) The 7 TM G-protein-coupled receptor target family. Chem Med Chem 1:761-782.
45. Jampel HD, Lynch MG, Brown RH, Kuhar MJ, and De Souza EB (1987) Beta-adrenergic receptors in human trabecular meshwork. Identification and autoradiographic localization. Invest Ophthalmol Vis Sci 28:772-779.
46. 1 cannabinoid receptor. J Pharmacol Exp Ther 308:880-886.
47. 2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697-1704.
48. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
49. Kenakin T (1995a) Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16:188-192.
50. Kenakin T (1995b) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
51. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
52. 1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 102:19144-19149.
53. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389.
54. Mackie K (2005) Cannabinoid receptor homo- and heterodimerization. Life Sci 77: 1667-1673.
55. Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, and Galzi JL (2007) A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 21:2124-2134.
56. Maneuf YP and Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
57. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
58. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, and Kelly ME (2007) Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152:1111-1120.
59. i protein interactions. Mol Pharmacol 67:2016-2024.
60. Pacher P and Haskó G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153:252-262.
61. Panetta R and Greenwood MT (2008) Physiological relevance of GPCR oligomerization and its impact on drug discovery. Drug Discov Today 13:1059-1066.
62. Pazos MR, Sagredo O, and Fernández-Ruiz J (2008) The endocannabinoid system in Huntington's disease. Curr Pharm Des 14:2317-2325.
63. Pertwee RG (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13:147-159.
64. Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30 (Suppl 1):S13-S18.
65. Pfleger KD and Eidne KA (2005) Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem J 385:625-637.
66. Piñeyro G (2009) Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling. Cell Signal 21:179-185.
67. Piomelli D, Giuffrida A, Calignano A, and Rodríguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218-224.
68. 1 receptor. Mol Pharmacol 68:1484-1495.
69. 1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395.
70. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, and Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
71. 1 receptors: the shape of things to come. Trends Pharmacol Sci 28:567-572.
72. 1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol 431:277-286.
73. Terrillon S and Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep 5:30-34.
74. 1 receptors in the rat central nervous system. Neuroscience 83:393-411.
75. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/ allosteric ligand. J Biol Chem 283:29312-29321.
76. Valant C, Sexton PM, and Christopoulos A (2009) Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv 9:125-135.
77. Vinod KY and Hungund BL (2006) Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 10:203-210.
78. 1 cannabinoid receptors as an example. Chem Phys Lipids 121:83-89.
79. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, and Whistler JL (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102:9050-9055.
80. Wanaka A, Kiyama H, Murakami T, Matsumoto M, Kamada T, Malbon CC, and Tohyama M (1989) Immunocytochemical localization of beta-adrenergic receptors in the rat brain. Brain Res 485:125-140.
81. Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, Das SK, DuBois RN, and Dey SK (2004) Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med 10:1074-1080.
82. Xie Z, Bhushan RG, Daniels DJ, and Portoghese PS (2005) Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 68:1079-1086.
83. Yan F, Mosier PD, Westkaemper RB, and Roth BL (2008) Gα-subunits differentially alter the conformation and agonist affinity of κ-opioid receptors. Biochemistry 47:1567-1578.